Related Experiment Videos

Integrative Mendelian Randomization and Single-Cell Pseudotime Analysis Reveal DKK3 as a PI3K-AKT-Modulated Driver of

Zhanghao Huang1,2,3, Tiegang Cao1,2,3, You Lang Zhou4

  • 1Medical School of Nantong University, Nantong University, Nantong, Jiangsu, China, ntu.edu.cn.

Human Mutation
|July 28, 2026
PubMed
Abstract

Insights

Dickkopf-3 (DKK3) drives esophageal squamous cell carcinoma (ESCC) progression by activating the PI3K-AKT pathway. This study identifies DKK3 as a potential therapeutic target and biomarker for this lethal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Esophageal squamous cell carcinoma (ESCC) is a lethal cancer with undefined molecular drivers.
  • The role of Dickkopf-3 (DKK3), a known modulator of oncogenic signaling, in ESCC is unclear.

Purpose of the Study:

  • To identify causal genes driving ESCC progression.
  • To investigate the specific role and mechanism of Dickkopf-3 (DKK3) in ESCC.

Main Methods:

  • Integrated Mendelian randomization (MR) with cis-expression quantitative trait loci (cis-eQTL) data and The Cancer Genome Atlas (TCGA) ESCC transcriptomic data.
  • Utilized single-cell RNA sequencing and in vitro/in vivo functional assays for gene prioritization and mechanistic validation.
  • Analyzed DKK3 expression, its effects on ESCC cell behavior, and associated signaling pathways (Gene Ontology, KEGG).

Main Results:

  • Identified 22 ESCC-associated genes, prioritizing DKK3, NINJ2, and SAPCD2.
  • DKK3 expression increased along the malignant epithelial trajectory in ESCC.
  • DKK3 knockdown inhibited ESCC cell proliferation, migration, and tumor growth, partly via PI3K-AKT pathway activation.

Conclusions:

  • Dickkopf-3 (DKK3) is a causally relevant oncogenic regulator in ESCC.
  • DKK3 promotes ESCC growth and migration through PI3K-AKT pathway activation.
  • DKK3 represents a potential therapeutic target and biomarker for ESCC.